Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Medical Malpractice Law & StrategyColumns & DepartmentsKickerLJN NewslettersSections

Drug & Device News

By ALM Staff | Law Journal Newsletters |
October 02, 2015

Risperdal Suits Heading To Trial

Two new trials against Janssen Pharmaceuticals over its anti-psychotic drug Risperdal are set for hearing this month. The cases, which are being tried on the plaintiff side by Thomas R. Kline of Kline and Specter and by Christopher A. Gomez and Stephen A. Sheller of Sheller P.C., claim that the company failed to warn the plaintiffs of the risk of developing gynecomastia, a condition in which males develop enlarged breasts. One previous case was settled pre-trial and another was decided in favor of the plaintiff, while in a third, the jury found Janssen negligent for failing to warn of the potential for abnormal breast development, yet also found that the plaintiff's particular breast development was not caused by Risperdal.

'

Eli Lilly Wins in First Bellwether Trial over Alleged Cymbalta Injuries

On Aug. 7, a federal jury rejected plaintiff Claudia Herrera's claim that she was injured because Eli Lilly and Co. failed to disclose that 44% of participants in clinical trials of their drug Cymbalta experienced withdrawal symptoms. Side effects claimed by the plaintiffs included electrical sensations in the brain (called “brain-zaps” in court filings), dizziness, nausea, vomiting, sweating, insomnia, nightmares and diarrhea. Cymbalta is used to treat depression, anxiety, fibromyalgia and pain. According to Eli Lilly's July U.S. Securities and Exchange Commission (SEC) quarterly filing, the company is currently facing about 65 lawsuits concerning Cymbalta.

'

Risperdal Suits Heading To Trial

Two new trials against Janssen Pharmaceuticals over its anti-psychotic drug Risperdal are set for hearing this month. The cases, which are being tried on the plaintiff side by Thomas R. Kline of Kline and Specter and by Christopher A. Gomez and Stephen A. Sheller of Sheller P.C., claim that the company failed to warn the plaintiffs of the risk of developing gynecomastia, a condition in which males develop enlarged breasts. One previous case was settled pre-trial and another was decided in favor of the plaintiff, while in a third, the jury found Janssen negligent for failing to warn of the potential for abnormal breast development, yet also found that the plaintiff's particular breast development was not caused by Risperdal.

'

Eli Lilly Wins in First Bellwether Trial over Alleged Cymbalta Injuries

On Aug. 7, a federal jury rejected plaintiff Claudia Herrera's claim that she was injured because Eli Lilly and Co. failed to disclose that 44% of participants in clinical trials of their drug Cymbalta experienced withdrawal symptoms. Side effects claimed by the plaintiffs included electrical sensations in the brain (called “brain-zaps” in court filings), dizziness, nausea, vomiting, sweating, insomnia, nightmares and diarrhea. Cymbalta is used to treat depression, anxiety, fibromyalgia and pain. According to Eli Lilly's July U.S. Securities and Exchange Commission (SEC) quarterly filing, the company is currently facing about 65 lawsuits concerning Cymbalta.

'

This premium content is locked for Entertainment Law & Finance subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
How Secure Is the AI System Your Law Firm Is Using? Image

In a profession where confidentiality is paramount, failing to address AI security concerns could have disastrous consequences. It is vital that law firms and those in related industries ask the right questions about AI security to protect their clients and their reputation.

COVID-19 and Lease Negotiations: Early Termination Provisions Image

During the COVID-19 pandemic, some tenants were able to negotiate termination agreements with their landlords. But even though a landlord may agree to terminate a lease to regain control of a defaulting tenant's space without costly and lengthy litigation, typically a defaulting tenant that otherwise has no contractual right to terminate its lease will be in a much weaker bargaining position with respect to the conditions for termination.

Pleading Importation: ITC Decisions Highlight Need for Adequate Evidentiary Support Image

The International Trade Commission is empowered to block the importation into the United States of products that infringe U.S. intellectual property rights, In the past, the ITC generally instituted investigations without questioning the importation allegations in the complaint, however in several recent cases, the ITC declined to institute an investigation as to certain proposed respondents due to inadequate pleading of importation.

The Power of Your Inner Circle: Turning Friends and Social Contacts Into Business Allies Image

Practical strategies to explore doing business with friends and social contacts in a way that respects relationships and maximizes opportunities.

Authentic Communications Today Increase Success for Value-Driven Clients Image

As the relationship between in-house and outside counsel continues to evolve, lawyers must continue to foster a client-first mindset, offer business-focused solutions, and embrace technology that helps deliver work faster and more efficiently.